Related Experiment Video
Updated: Apr 7, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients
Vicente Soriano1, Juan Berenguer
1aHospital Universitario La Paz bInstituto de Investigación Sanitaria La Paz cHospital General Universitario Gregorio Marañón dInstituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Insights
HIV and hepatitis C virus (HCV) coinfection accelerates liver fibrosis. Extrahepatic manifestations of HCV are common in coinfected patients and may be reduced by antiviral therapy.
Area of Science:
- Hepatology
- Infectious Diseases
- Immunology
Background:
- HIV infection accelerates hepatitis C virus (HCV)-related liver fibrosis, increasing risks of cirrhosis and liver decompensation.
- Extrahepatic manifestations of HCV significantly contribute to morbidity and mortality in chronic hepatitis C patients.
- HCV primarily targets the liver, but its systemic effects are increasingly recognized.
Purpose of the Study:
- To review current data on extrahepatic comorbidities associated with HCV in HIV-infected patients.
- To understand the impact of HCV on non-liver related conditions in coinfected individuals.
Main Methods:
- Literature review of current data on extrahepatic manifestations in HIV/HCV coinfection.
- Analysis of studies examining comorbidities in coinfected populations.
Main Results:
- A significant proportion of HIV/HCV coinfected individuals exhibit extrahepatic manifestations.
- These manifestations include autoimmune disorders, lymphoproliferative diseases, and cardiovascular, renal, metabolic, and CNS issues.
- Chronic immune activation and systemic inflammation in both HIV and HCV contribute to these comorbidities.
Conclusions:
- Extrahepatic manifestations of HCV represent a substantial burden of morbidity and mortality in coinfected patients.
- Successful antiviral therapy leading to HCV eradication may reduce both hepatic and extrahepatic manifestations.
Purpose Of Review:
HIV infection facilitates progression of hepatitis C virus (HCV)-related liver fibrosis, thus increasing the risk of cirrhosis and decompensated liver disease. Although the primary target of HCV infection is the liver, extrahepatic manifestations related to HCV contribute significantly to morbidity and mortality in patients with chronic hepatitis C. We review current data on extrahepatic comorbidities associated with HCV in HIV-infected patients.
Recent Findings:
A large proportion of individuals coinfected with HIV/HCV has extrahepatic manifestations that may be indirectly or directly related to HCV infection. Extrahepatic manifestations include autoimmune and/or lymphoproliferative disorders, and cardiovascular, renal, metabolic, and central nervous system manifestations. Chronic immune activation and systemic inflammation, hallmarks of both HIV and HCV infection, may contribute greatly to extrahepatic comorbidities of HCV in this population group. There is substantial evidence that successful antiviral therapy might reduce both hepatic and extrahepatic manifestations of HCV infection in patients coinfected with HIV/HCV.
Summary:
A substantial burden of the morbidity and the mortality related to HCV in patients with or without HIV infection depends on its extrahepatic manifestations. HCV eradication following successful antiviral therapy might reduce both.
Related Concept Videos
Hepatitis
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Drug Excretion: Influencing Factors

